Maraba Virus Oncolytic Platform for CNS Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective and safe oncolytic agents that can selectively target and kill cancer cells while minimizing harm to normal cells, particularly for central nervous system cancers, where existing viruses like VSV are neurovirulent and have safety concerns.
Innovation Solution
Development of a recombinant oncolytic Maraba virus platform with specific mutations in the M and G proteins, such as Q242R and L123W, which increases its therapeutic index by being more virulent in tumor cells than wild-type virus, allowing for systemic delivery and treatment of both primary and secondary CNS cancers with reduced neurovirulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VSV is used as an oncolytic agent, then tumor cell killing efficacy is improved, but neurovirulence and safety concerns worsen
Solution Approach 1:
The patent applies local quality by creating rhabdovirus variants with specific mutations (Q242R in G protein, L123W in M protein) that locally modify viral properties to reduce neurovirulence while preserving oncolytic activity. The mutations are introduced at specific positions in the viral genome to achieve differential effects on neuronal versus tumor cells.
Solution Approach 2:
The patent employs parameter changes by altering the amino acid sequence of viral proteins through point mutations. The Q242R mutation in the G protein and L123W mutation in the M protein change the physical-chemical parameters of the viral structure, resulting in reduced affinity for neuronal cell receptors while maintaining tumor cell infection capability.
2Productivity
If wild-type rhabdovirus is used, then tumor cell killing ability is improved, but safety profile and selective toxicity worsen
Solution Approach 1:
The patent applies local quality by creating rhabdovirus variants with specific mutations (Q242R in G protein, L123W in M protein) that locally modify viral properties to reduce neurovirulence while preserving oncolytic activity. The mutations are introduced at specific positions in the viral genome to achieve differential effects on neuronal versus tumor cells.
Solution Approach 2:
The patent converts the potentially harmful neurovirulence of rhabdoviruses into a benefit by using the same viral platform to target tumor cells selectively. The mutations redirect the virus's high infectivity away from neuronal cells and toward tumor cells, transforming a safety hazard into a therapeutic advantage.
3Adaptability or versatility
If existing oncolytic viruses are used for CNS cancers, then treatment coverage is improved, but safety and immune response issues worsen
Solution Approach 1:
The patent applies universality by developing a rhabdovirus platform that can treat multiple types of cancers including CNS tumors, glioblastoma, and metastatic disease. The virus maintains broad adaptability to infect various tumor cell types while the mutations provide universal protection against neurovirulence across different administration routes and patient populations.
Data Source
AI summary
Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.